Side-by-side comparison of AI visibility scores, market position, and capabilities
Victor NY Mexican beer imports (NYSE: STZ) ~$9.8B FY2025 revenue; Modelo Especial #1 US beer brand since June 2023, Corona/Pacifico, wine portfolio review, competing with ABI and Molson Coors.
Constellation Brands, Inc. is a Victor, New York-based beer, wine, and spirits company — publicly traded on the New York Stock Exchange (NYSE: STZ) as an S&P 500 Consumer Staples component — producing and marketing the United States rights to Mexican beer brands including Modelo Especial, Corona Extra, Pacifico, and Modelo Negra (acquired from Anheuser-Busch InBev as a condition of ABI's 2013 Grupo Modelo acquisition), and a wine and spirits portfolio including Robert Mondavi, Kim Crawford, The Prisoner, Meiomi, and High West whiskey through approximately 10,000 employees. In fiscal year 2025 (ending February 2025), Constellation Brands reported revenues of approximately $9.8 billion, with the Beer Division (Modelo, Corona, Pacifico) generating approximately $8.4 billion (+4-5% organic growth) as Modelo Especial maintained its status as the #1-selling beer in the United States by dollar sales — a position Modelo captured from Bud Light in June 2023 following the Bud Light controversy and has held since. CEO Bill Newlands retired in 2024, with Garth Hankinson succeeding him, maintaining Constellation's strategy of investing behind the Modelo brand family's premium Hispanic-heritage positioning as the fastest-growing segment of US beer consumers (Hispanic adult beer drinkers choosing culturally authentic imported Mexican lagers over domestic brands). The Wine and Spirits segment faced significant headwinds from premiumization-to-value trading and market share pressure — Constellation announced a strategic review of the Wine and Spirits portfolio in 2024, exploring potential divestitures to focus capital exclusively on the Beer Division's high-margin, high-growth beer brands.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.